Literature DB >> 6797661

Comparison of haemodynamic responses to dobutamine and salbutamol in cardiogenic shock after acute myocardial infarction.

M B Fowler, A D Timmis, J P Crick, R Vincent, D A Chamberlain.   

Abstract

Nine patients with critically reduced cardiac output after acute myocardial infarction underwent a single cross-over comparison of dobutamine and salbutamol to compare the haemodynamic effects of these drugs, which have, respectively, predominantly beta 1-adrenergic and beta 2-adrenergic agonist activity. The responses were used to select the more appropriate treatment for individual patients. Only relatively small responses were obtained: those with poorest baseline measurements tended to show the least effect. When the results from the series were averaged, dobutamine (250-750 microgram/min) caused a small but progressive increase in cardiac index (1.8 to 2.2 1/min/m2) throughout the dose range. Systemic blood pressure was not increased, and calculated systemic vascular resistance fell from 25 to 19 units. Heart rate rose from 107 to 118 beats/min and stroke index from 17 to 19 ml/beat/m2. Pulmonary artery end-diastolic pressure fell from 18 to 15 mm Hg. Salbutamol (10-40 microgram/min) produced a similar progressive increase in cardiac index, from 1.6 to 2.21/min/m2. Systemic blood pressure was not altered, and systemic vascular resistance fell from 25 to 20 units. Heart rate rose from 105 to 119 beats/min and stroke index from 16 to 19 ml/beat/m2. Pulmonary artery end-diastolic pressure did not fall. Dobutamine and salbutamol have closely similar haemodynamic effects when used in cardiogenic shock after acute myocardial infarction. Both drugs increase cardiac index but heart rate also rises, and the increase in stroke index is relatively small. Mean arterial pressure is altered little by either agent, but dobutamine (in contrast with dopamine) tends to reduce pulmonary artery end-diastolic pressure, which may be beneficial.

Entities:  

Mesh:

Substances:

Year:  1982        PMID: 6797661      PMCID: PMC1495709          DOI: 10.1136/bmj.284.6309.73

Source DB:  PubMed          Journal:  Br Med J (Clin Res Ed)        ISSN: 0267-0623


  11 in total

1.  Clinical cardiovascular pharmacology of dobutamine. A selective inotropic catecholamine.

Authors:  D Jewitt; J Birkhead; A Mitchell; C Dollery
Journal:  Lancet       Date:  1974-08-17       Impact factor: 79.321

2.  Beta adrenoceptor blockade in acute myocardial infarction.

Authors:  R M Norris
Journal:  Am Heart J       Date:  1980-06       Impact factor: 4.749

3.  Regional streptokinase in myocardial infarction.

Authors:  R C Leinbach; H K Gold
Journal:  Circulation       Date:  1981-03       Impact factor: 29.690

4.  Dobutamine: development of a new catecholamine to selectively increase cardiac contractility.

Authors:  R R Tuttle; J Mills
Journal:  Circ Res       Date:  1975-01       Impact factor: 17.367

5.  Comparison of dobutamine and dopamine in treatment of severe heart failure.

Authors:  J D Stoner; J L Bolen; D C Harrison
Journal:  Br Heart J       Date:  1977-05

6.  Comparative systemic and regional hemodynamic effects of dopamine and dobutamine in patients with cardiomyopathic heart failure.

Authors:  C V Leier; P T Heban; P Huss; C A Bush; R P Lewis
Journal:  Circulation       Date:  1978-09       Impact factor: 29.690

7.  Effects of dobutamine in patients with acute myocardial infarction.

Authors:  T A Gillespie; H D Ambos; B E Sobel; R Roberts
Journal:  Am J Cardiol       Date:  1977-04       Impact factor: 2.778

8.  Early intravenous atenolol treatment in suspected acute myocardial infarction. Preliminary report of a randomised trial.

Authors:  S Yusuf; D Ramsdale; R Peto; L Furse; D Bennett; C Bray; P Sleight
Journal:  Lancet       Date:  1980-08-09       Impact factor: 79.321

9.  A comparison of digoxin and dobutamine in patients with acute infarction and cardiac failure.

Authors:  R A Goldstein; E R Passamani; R Roberts
Journal:  N Engl J Med       Date:  1980-10-09       Impact factor: 91.245

10.  Comparison of haemodynamic responses to dopamine and salbutamol in severe cardiogenic shock complicating acute myocardial infarction.

Authors:  A D Timmis; M B Fowler; D A Chamberlain
Journal:  Br Med J (Clin Res Ed)       Date:  1981-01-03
View more
  6 in total

1.  Cardiac implications for the use of beta2-adrenoceptor agonists for the management of muscle wasting.

Authors:  Peter Molenaar; Lu Chen; William A Parsonage
Journal:  Br J Pharmacol       Date:  2006-03       Impact factor: 8.739

2.  The effect of salbutamol on performance in endurance cyclists.

Authors:  S R Norris; S R Petersen; R L Jones
Journal:  Eur J Appl Physiol Occup Physiol       Date:  1996

Review 3.  Salbutamol in the 1980s. A reappraisal of its clinical efficacy.

Authors:  A H Price; S P Clissold
Journal:  Drugs       Date:  1989-07       Impact factor: 9.546

4.  The effects of dopexamine on the cardiovascular system of the dog.

Authors:  R A Brown; J B Farmer; J C Hall; R G Humphries; S E O'Connor; G W Smith
Journal:  Br J Pharmacol       Date:  1985-07       Impact factor: 8.739

5.  Vasoactive pharmacologic therapy in cardiogenic shock: a critical review.

Authors:  Rasha Kaddoura; Amr Elmoheen; Ehab Badawy; Mahmoud F Eltawagny; Mohamed A Seif; Khalid Bashir; Amar M Salam
Journal:  J Drug Assess       Date:  2021-07-20

Review 6.  The spectrum of cardiovascular effects of dobutamine - from healthy subjects to septic shock patients.

Authors:  Arnaldo Dubin; Bernardo Lattanzio; Luis Gatti
Journal:  Rev Bras Ter Intensiva       Date:  2017 Oct-Dec
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.